On Thursday, Shares of SunEdison, Inc. (NYSE:SUNE), lost -10.17% to $12.10.
SunEdison declared that it has closed financing and begun construction on one of its largest solar power plants to date, the 156 megawatt (MW) DC / 120 MW AC Comanche Solar project in Pueblo, Colo. When accomplished, the Comanche Solar project will be the largest solar power plant east of the Rocky Mountains.
The Comanche solar power plant will be the largest in Colorado and is predictable to produce more than 300 gigawatt-hours of energy a year, enough to power about 30,000 Colorado homes. The solar power plant will avoid the emission of more than 478 million pounds of carbon dioxide, the equivalent of taking more than 45,000 passenger vehicles off the road.
Public Service Company of Colorado, a partner of Xcel Energy (XEL) with more than 1.4 million customers, will purchase electricity generated by the solar power plant under a 25-year power purchase agreement with SunEdison. The power contract was awarded as part of an open solicitation where Comanche Solar was selected as preferred to other forms of energy, counting natural gas.
SunEdison, Inc. develops, manufactures, and sells silicon wafers to the semiconductor industry. The company operates through three segments: Solar Energy, TerraForm Power, and Semiconductor Materials.
Shares of Eli Lilly and Company (NYSE:LLY), inclined 4.25% to $87.33, during its last trading session.
Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), the first and only concentrated mealtime insulin analog in the U.S., is now available in pharmacies, Eli Lilly and Company (LLY) declared recently. Humalog U-200 KwikPen is a prefilled pen containing a concentrated formulation of Lilly’s rapid-acting insulin Humalog® (insulin lispro 100 units/mL) to improve glycemic control in people with type 1 and type 2 diabetes. It is intended for people who are already taking mealtime insulin.
Humalog U-200 KwikPen holds twice as many units of insulin (600 units vs. 300 units) as the U-100 formulation in the same three-milliliter cartridge volume, offering patients a pen that lasts longer, which facilitates fewer pen changes every month. This may assist patients who require higher daily doses of mealtime insulin fit their treatment into their lives.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products.
Finally, Oasis Petroleum Inc. (NYSE:OAS), ended its last trade with -5.11% loss, and closed at $9.66, as Crude oil prices are ongoing their yearlong plunge amid the global oil supply glut and some analysts think the commodity’s decline will only get worse before it gets better, according to Fortune.
The price of U.S. oil has fell to nearly $40 per barrel this week — its lowest point in six years and nearly a 60% decline from last summer’s highs — and The Wall Street Journal reports that analysts at Citigroup think there is “a 90% likelihood” that the price will drop closer to $30 a barrel very soon.
Oasis Petroleum Inc., an independent exploration and production company, focuses on the acquisition and development of unconventional oil and natural gas resources in the North Dakota and Montana regions of the Williston Basin.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
